Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 832 matching drugs for EP300 — including drugs targeting any of its 195 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
olaparib PARP1 SSL via PARP1 yes 1
osimertinib EGFR SSL via EGFR yes 1
vorasidenib IDH1 SSL via IDH1 yes 1
sunitinib KIT SSL via KIT yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab KIT SSL via KIT 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RAF1 SSL via RAF1 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab RET SSL via RET 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) KIT SSL via KIT 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RAF1 SSL via RAF1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) RET SSL via RET 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ALK SSL via ALK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK4 SSL via CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KIT SSL via KIT 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK14 SSL via MAPK14 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib MAPK3 SSL via MAPK3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RAF1 SSL via RAF1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib RET SSL via RET 3
crizotinib ALK SSL via ALK yes 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan TOP1MT SSL via TOP1MT 3
lurbinectedin, irinotecan TOP1MT SSL via TOP1MT 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone PPARG SSL via PPARG 3
nivolumab or pembrolizumab (dependent upon approved indication), metformin, rosiglitazone RXRB SSL via RXRB 3
pembrolizumab, belzutifan, lenvatinib KIT SSL via KIT 3
pembrolizumab, belzutifan, lenvatinib RET SSL via RET 3
abemaciclib CDK4 SSL via CDK4 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ALK SSL via ALK 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RAF1 SSL via RAF1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel RET SSL via RET 2
alectinib, stereotactic radiosurgery ALK SSL via ALK 2
alvocidib, paclitaxel CDK1 SSL via CDK1 2
alvocidib, paclitaxel CDK4 SSL via CDK4 2
alvocidib, paclitaxel CDK5 SSL via CDK5 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
apatinib, irinotecan TOP1MT SSL via TOP1MT 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TOP1MT SSL via TOP1MT 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TOP1MT SSL via TOP1MT 2
avapritinib KIT SSL via KIT yes 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment KIT SSL via KIT 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment MAPK14 SSL via MAPK14 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK4 SSL via CDK4 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging TLR9 SSL via TLR9 2
bortezomib PSMB5 SSL via PSMB5 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
bryostatin 1, paclitaxel PRKCE SSL via PRKCE 2
cabozantinib RET SSL via RET 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib RET SSL via RET 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy CA3 SSL via CA3 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery TOP1MT SSL via TOP1MT 2
cpt- 11, cisplatin, celecoxib, radiation, surgery CA3 SSL via CA3 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK4 SSL via CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ALK SSL via ALK 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib RET SSL via RET 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC3 SSL via HDAC3 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a KIT SSL via KIT 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a RET SSL via RET 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TOP1MT SSL via TOP1MT 2
irinotecan, capecitabine TOP1MT SSL via TOP1MT 2
irinotecan, docetaxel TOP1MT SSL via TOP1MT 2
lenvatinib, pembrolizumab KIT SSL via KIT 2
lenvatinib, pembrolizumab RET SSL via RET 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate KIT SSL via KIT 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate RET SSL via RET 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab TOP1MT SSL via TOP1MT 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells CHRNB4 SSL via CHRNB4 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a KIT SSL via KIT 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a RET SSL via RET 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine TOP2A SSL via TOP2A 2
palbociclib CDK4 SSL via CDK4 yes 2
pazopanib KIT SSL via KIT yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC3 SSL via HDAC3 2
pembrolizumab, lenvatinib KIT SSL via KIT 2
pembrolizumab, lenvatinib RET SSL via RET 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu KIT SSL via KIT 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu RET SSL via RET 2
pembrolizumab, paclitaxel, docetaxel, irinotecan TOP1MT SSL via TOP1MT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin KIT SSL via KIT 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin RET SSL via RET 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery RET SSL via RET 2
regorafenib KIT SSL via KIT yes 2
regorafenib RAF1 SSL via RAF1 yes 2
regorafenib RET SSL via RET yes 2
regorafenib, laboratory biomarker analysis KIT SSL via KIT 2
regorafenib, laboratory biomarker analysis RAF1 SSL via RAF1 2
regorafenib, laboratory biomarker analysis RET SSL via RET 2
sorafenib, administered orally, ct/mri KIT SSL via KIT 2
sorafenib, administered orally, ct/mri RAF1 SSL via RAF1 2
sorafenib, administered orally, ct/mri RET SSL via RET 2
topotecan TOP1MT SSL via TOP1MT 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC3 SSL via HDAC3 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy (imrt), temozolomide, chloroquine, tumor treating fields therapy (ttf) TLR9 SSL via TLR9 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC3 SSL via HDAC3 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin TOP1MT SSL via TOP1MT 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan TOP1MT SSL via TOP1MT 1
abemaciclib, abemaciclib CDK4 SSL via CDK4 1
abemaciclib, bevacizumab CDK4 SSL via CDK4 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.